Clinical outcomes with PD1/PDL1 inhibition were encouraging in CRC patients whose tumors were mismatch repair–deficient (MMRd)/microsatellite instability-high (MSI-H) (54), while responses were rarely seen with mismatch repair–proficient (MMRp)/MSS tumors (55, 56). Here, CD274 is linked to colorectal carcinoma.